Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 601 to 650 of 2522

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA803
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglyceridesTA805
Belimumab for treating lupus nephritis (terminated appraisal)TA806
Roxadustat for treating symptomatic anaemia in chronic kidney diseaseTA807
ProciseDx point-of-care platform for inflammatory bowel diseaseMIB302
Fenfluramine for treating seizures associated with Dravet syndromeTA808
Setmelanotide for treating obesity caused by LEPR or POMC deficiencyHST21
Social, emotional and mental wellbeing in primary and secondary educationNG223
RespiraSense for continuously monitoring respiratory rateMIB299
Cyanoacrylate glue for hernia mesh fixationMIB301
MiraQ for assessing graft flow during coronary artery bypass graft surgeryHTG275
Teduglutide for treating short bowel syndromeTA804
Vertebral body tethering for idiopathic scoliosis in children and young peopleIPG728
Nerve graft for corneal denervationIPG729
Type 2 diabetes in adults: managementNG28
Depression in adults: treatment and managementNG222
Faricimab for treating diabetic macular oedemaTA799
Faricimab for treating wet age-related macular degenerationTA800
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancerTA801
Cemiplimab for treating advanced cutaneous squamous cell carcinomaTA802
Multiple sclerosis in adults: managementNG220
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Reducing sexually transmitted infectionsNG221
Venetoclax for treating chronic lymphocytic leukaemiaTA796
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)TA797
Preterm labour and birthNG25
Gout: diagnosis and managementNG219
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)TA793
Diroximel fumarate for treating relapsing–remitting multiple sclerosisTA794
Ibrutinib for treating Waldenstrom's macroglobulinaemiaTA795
Peristeen Plus transanal irrigation system for managing bowel dysfunctionHTG462
Thopaz+ portable digital system for managing chest drainsHTG465
Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus)IPG727
Filgotinib for treating moderately to severely active ulcerative colitisTA792
Social work with adults experiencing complex needsNG216
Endoanchoring systems in endovascular aortic aneurysm repairIPG725
Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritisIPG726
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)TA790
Romosozumab for treating severe osteoporosisTA791
Sleepio to treat insomnia and insomnia symptomsHTG624
Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndromeIPG724
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsTA789
Vaccine uptake in the general populationNG218
Vaccine uptake in under 19sQS145
Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adultsES40
Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infectionsES39
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyTA788
ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesionsMIB295
Granulox for managing chronic non-healing woundsMIB296
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and overHST20

Results per page

  1. 10
  2. 25
  3. 50
  4. All